Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 3/2017

01-03-2017 | Review Article

Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Author: Rashmi R. Shah

Published in: Drug Safety | Issue 3/2017

Login to get access

Abstract

Signalling pathways involving protein kinase, insulin-like growth factor 1, insulin receptors and the phosphoinositide 3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) system are critical in promoting oncogenesis. The use of anticancer agents that inhibit these pathways frequently results in hyperglycaemia, an on-target effect of these drugs. Hyperglycaemia induced by these agents denotes optimal inhibition of the desired pharmacological target. As hyperglycaemia can be treated successfully and effectively with metformin, managing this complication by reducing the dose of or discontinuing the anticancer drug may be counterproductive, especially if it is otherwise effective and clinically tolerated. The use of metformin to treat hyperglycaemia induced by anticancer drugs provides a valuable therapeutic opportunity of potentiating their clinical anticancer effects. Although evidence from randomised controlled trials is awaited, extensive preclinical evidence and clinical observational studies suggest that metformin has anticancer properties that improve overall survival in patients with diabetes and a variety of cancers. Metformin has also been reported to reverse resistance to epidermal growth factor receptor (EGFR)-inhibiting tyrosine kinase inhibitors. This review summarises briefly the role of the above signalling pathways in oncogenesis, the causal association between inhibition of these pathways and hyperglycaemia, and the effect of metformin on clinical outcomes resulting from its anticancer properties. The evidence reviewed herein, albeit almost exclusively from observational studies, provides support for a greater use of metformin not only in patients with cancer and diabetes or drug-induced hyperglycaemia but also potentially as an anticancer drug. However, prospective randomised controlled studies are needed in all these settings to better assess the effect on clinical outcomes of adding metformin to ongoing anticancer therapy.
Literature
1.
Shah RR. Tyrosine kinase inhibitors-induced interstitial lung disease: clinical features, diagnostic challenges and therapeutic dilemmas. Drug Saf. 2016;39:1073–91.PubMedCrossRef
2.
Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today. 2016;21:5–10.PubMedCrossRef
3.
Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol. 2011;29:2543–9.PubMedCrossRef
4.
Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, et al. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2013;69:151–9.PubMedCrossRef
5.
Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, et al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015;94:213–27.PubMedCrossRef
6.
Liu J, Sheng Z, Zhang Y, Li G. The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for molecularly selected patients with non-small cell lung cancer: a meta-analysis of 30 randomized controlled trials. Target Oncol. 2016;11:49–58.PubMedCrossRef
7.
Guetz GD, Landre T, Uzzan B, Chouahnia K, Nicolas P, Morere JF. Is there a survival benefit of first-line epidermal growth factor receptor tyrosine kinase inhibitor monotherapy versus chemotherapy in patients with advanced non-small-cell lung cancer? A meta-analysis. Target Oncol. 2016;11:41–7.PubMedCrossRef
8.
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013;36:413–26.PubMedCrossRef
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17:197–202.PubMedCrossRef
20.
Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:643–56.PubMedCrossRef
21.
Malek R, Davis SN. Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. Expert Opin Investig Drugs. 2016;25:287–96.PubMedCrossRef
22.
23.
Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res. 2015;4:576–83.PubMedPubMedCentral
24.
Ma H, Zhang T, Shen H, Cao H, Du J. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol. 2014;77:917–28.PubMedCrossRef
25.
Hartog H, Wesseling J, Boezen HM, van der Graff WTA. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer. 2007;43:1895–904.PubMedCrossRef
26.
Lundby A, Bolvig P, Hegelund AC, Hansen BF, Worm J, Lützen A, et al. Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues. J Appl Toxicol. 2015;35:842–50.PubMedCrossRef
27.
Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest. 2016;39:1365–76.PubMedCrossRef
28.
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852–7.PubMedCrossRef
29.
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol. 2011;22:68–73.PubMedCrossRef
30.
31.
Anastassiadis T, Duong-Ly KC, Deacon SW, Lafontant A, Ma H, Devarajan K, et al. A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor. J Biol Chem. 2013;288:28068–77.PubMedPubMedCentralCrossRef
32.
Jin M, Wang J, Buck E, Mulvihill MJ. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. Future Med Chem. 2012;4:315–28.PubMedCrossRef
33.
34.
Allison M. Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers. Nat Biotechnol. 2012;30:906–7.PubMedCrossRef
35.
36.
37.
Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011;16(Suppl 1):12–9.PubMedCrossRef
38.
Subramani R, Lopez-Valdez R, Arumugam A, Nandy S, Boopalan T, Lakshmanaswamy R. Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS One. 2014;9(5):e97016.PubMedPubMedCentralCrossRef
39.
40.
Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015;22:33–48.PubMedPubMedCentralCrossRef
41.
42.
Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28.PubMedCrossRef
43.
Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. mTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. (Epub 2016 Oct 4).
44.
Li J, Dang Y, Gao J, Li Y, Zou J, Shen L. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Med Oncol. 2015;32:111.PubMedCrossRef
45.
46.
Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, et al. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer. 2013;49:1799–807.PubMedCrossRef
47.
Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013;49:3219–28.PubMedCrossRef
48.
Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:191–200.PubMedPubMedCentralCrossRef
49.
Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61:452–6.PubMedCrossRef
50.
Doi T, Shitara K, Kojima T, Yoshino T, Dontabhaktuni A, Rebscher H, et al. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77:1253–62.PubMedCrossRef
51.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, et al. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 2015;20:737–41.PubMedPubMedCentralCrossRef
52.
Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17:6304–12.PubMedCrossRef
53.
Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013;72:643–52.PubMedPubMedCentralCrossRef
54.
Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012;118:4795–800.PubMedCrossRef
55.
Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65:765–73.PubMedCrossRef
56.
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, et al. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014;32:518–25.CrossRef
57.
Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J, et al. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemother Pharmacol. 2016;77:1303–14.PubMedCrossRef
58.
Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:701–11.PubMedCrossRef
59.
Schwartz GK, Dickson MA, LoRusso PM, Sausville EA, Maekawa Y, Watanabe Y, et al. Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity. Cancer Sci. 2016;107:499–506.PubMedPubMedCentralCrossRef
60.
Desai J, Solomon BJ, Davis ID, Lipton LR, Hicks R, Scott AM, et al. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J Clin Oncol. 2010;28(Suppl):3104.
61.
62.
63.
64.
Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma—systematic review and meta-analysis. Cancer Med. 2013;2:862–71.PubMedPubMedCentralCrossRef
65.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014;40:190–6.PubMedCrossRef
66.
Lew S, Chamberlain RS. Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: meta-analysis. Anticancer Res. 2016;36:1711–8.PubMed
67.
Xu KY, Shameem R, Wu S. Risk of hyperglycemia attributable to everolimus in cancer patients: a meta-analysis. Acta Oncol. 2016;55(1196–203):68.
68.
Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, et al. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2012;42:836–44.PubMedCrossRef
69.
Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. Br J Cancer. 2013;109:1711–6.PubMedPubMedCentralCrossRef
70.
Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33:3576–82.PubMedCrossRef
71.
Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol. 2006;17:2236–44.PubMedCrossRef
72.
Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res. 2009;15:217–25.PubMedCrossRef
73.
74.
Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, et al. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist. 2016;21:855–60.PubMedCrossRef
75.
Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688–95.PubMedCrossRef
76.
Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77:787–95.PubMedPubMedCentralCrossRef
77.
Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. (Epub 2016 Sep 7).
78.
Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014;74:359–65.PubMedPubMedCentralCrossRef
79.
Lee Y, Jung HS, Choi HJ, Kim MJ, Kim TM, Park KS, et al. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report. Diabetes Res Clin Pract. 2011;93:e68–70.PubMedCrossRef
80.
Demirci A, Bal O, Durnali A, Ekinci AŞ, Eşbah O, Alkiş N, et al. Sunitinib-induced severe hypoglycemia in a diabetic patient. J Oncol Pharm Pract. 2014;20:469–72.PubMedCrossRef
81.
Fountas A, Tigas S, Giotaki Z, Petrakis D, Pentheroudakis G, Tsatsoulis A. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens). 2015;14:438–41.PubMed
82.
Ohn JH, Kim YG, Lee SH, Jung HS. Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinol Metab (Seoul). 2013;28:149–52.PubMedPubMedCentralCrossRef
83.
Huda MS, Amiel SA, Ross P, Aylwin SJ. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014;37:e87–8.PubMedCrossRef
84.
Thijs AM, Tack CJ, van der Graaf WT, Rongen GA, van Herpen CM. The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. Br J Clin Pharmacol. 2016;81:768–72.PubMedCrossRef
85.
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369–80.PubMedCrossRef
86.
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.PubMedCrossRef
87.
88.
Wojciechowska J, Krajewski W, Bolanowski M, Kręcicki T, Zatoński T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124:263–75.PubMedCrossRef
89.
Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56:1304–19.PubMedPubMedCentralCrossRef
90.
Daugan M, Dufaÿ Wojcicki A, d’Hayer B, Boudy V. Metformin: an anti-diabetic drug to fight cancer. Pharmacol Res. 2016;113:675–85.PubMedCrossRef
91.
92.
Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, et al. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem. 2014;289:27692–701.PubMedPubMedCentralCrossRef
93.
Bhaw-Luximon A, Jhurry D. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol. 2016;142:2159–71.PubMedCrossRef
94.
Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012;32:1627–37.PubMed
95.
Wang Y, Wei J, Li L, Fan C, Sun Y. Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells. Oncol Res. 2014;22:193–201.PubMedCrossRef
96.
Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31–43.PubMedCrossRef
97.
Coperchini F, Leporati P, Rotondi M, Chiovato L. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest. 2015;38:1047–55.PubMedCrossRef
98.
Zhang HH, Guo XL. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016;78:13–26.PubMedCrossRef
99.
Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7:40767–80.PubMedPubMedCentral
100.
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714–26.PubMedCrossRef
101.
Li L, Wang Y, Peng T, Zhang K, Lin C, Han R, et al. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget. 2016;7:34442–52.PubMedPubMedCentral
102.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662–73.PubMedPubMedCentralCrossRef
103.
Peng M, Huang Y, Tao T, Peng CY, Su Q, Xu W, et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Sci Rep. 2016;6:28611.PubMedPubMedCentralCrossRef
104.
Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer. 2014;14:172.PubMedPubMedCentralCrossRef
105.
106.
Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8:e71583.PubMedPubMedCentralCrossRef
107.
Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7:867–85.PubMedPubMedCentralCrossRef
108.
Lin HC, Kachingwe BH, Lin HL, Cheng HW, Uang YS, Wang LH. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. Pharmacotherapy. 2014;34:36–45.PubMedCrossRef
109.
110.
Tseng CH. Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur J Cancer. 2016;52:19–25.PubMedCrossRef
111.
Tseng CH. Response to Letter to the Editor on comments on “Use of metformin and risk of kidney cancer in patients with type 2 diabetes”. Eur J Cancer. 2016;61:159–60.PubMedCrossRef
112.
Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–61.PubMedCrossRef
113.
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–5.PubMedPubMedCentralCrossRef
114.
Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5:10147.PubMedPubMedCentralCrossRef
115.
Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012;55:2593–603.PubMedCrossRef
116.
Golozar A, Liu S, Lin JA, Peairs K, Yeh HC. Does metformin reduce cancer risks? Methodologic considerations. Curr Diab Rep. 2016;16:4.PubMedCrossRef
117.
Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of renal cell carcinoma: a case–control analysis. Eur J Cancer Prev. (Epub 2016 Mar 3).
118.
Becker C, Jick SS, Meier CR, Bodmer M. No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case–control study. BMC Cancer. 2015;15:719.PubMedPubMedCentralCrossRef
119.
Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of head and neck cancer: a case–control analysis. Diabetes Obes Metab. 2014;16:1148–54.PubMedCrossRef
120.
Becker C, Meier CR, Jick SS, Bodmer M. Case–control analysis on metformin and cancer of the esophagus. Cancer Causes Control. 2013;24:1763–70.PubMedCrossRef
121.
Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: a case–control analysis. Gynecol Oncol. 2013;129:565–9.PubMedCrossRef
122.
Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist. 2013;18:1248–55.PubMedPubMedCentralCrossRef
123.
Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015;191:448–54.PubMedPubMedCentralCrossRef
124.
Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, et al. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Lett. 2015;369:97–102.PubMedCrossRef
125.
Xu T, Liang G, Yang L, Zhang F. Prognosis of small cell lung cancer patients with diabetes treated with metformin. Clin Transl Oncol. 2015;17:819–24.PubMedCrossRef
126.
Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, et al. Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Tumour Biol. 2015;36:8101–6.PubMedCrossRef
127.
Wink KC, Belderbos JS, Dieleman EM, Rossi M, Rasch CR, Damhuis RA, et al. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol. 2016;118:453–9.PubMedCrossRef
128.
Wan G, Yu X, Chen P, Wang X, Pan D, Wang X, et al. Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget. 2016;7:35437–45.PubMedPubMedCentral
129.
Tian RH, Zhang YG, Wu Z, Liu X, Yang JW, Ji HL. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Clin Transl Oncol. 2016;18:641–9.PubMedCrossRef
130.
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18:2905–12.PubMedPubMedCentralCrossRef
131.
Lee SH, Yoon SH, Lee HS, Chung MJ, Park JY, Park SW, et al. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Dig Liver Dis. 2016;48:435–40.PubMedCrossRef
132.
Cerullo M, Gani F, Chen SY, Canner J, Pawlik TM. Metformin use is associated with improved survival in patients undergoing resection for pancreatic cancer. J Gastrointest Surg. 2016;20:1572–80.PubMedCrossRef
133.
Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP. Effect of metformin use on survival in resectable pancreatic cancer: a single-institution experience and review of the literature. PLoS One. 2016;11:e0151632.PubMedPubMedCentralCrossRef
134.
Keizman D, Ish-Shalom M, Sella A, Gottfried M, Maimon N, Peer A, et al. Metformin use and outcome of sunitinib treatment in patients with diabetes and metastatic renal cell carcinoma. Clin Genitourin Cancer. 2016;14:420–5.PubMedCrossRef
135.
Cheng JJ, Li H, Tan HS, Tan PH, Ng LG, Ng QS, et al. Metformin use in relation with survival outcomes of patients with renal cell carcinoma. Clin Genitourin Cancer. 2016;14:168–75.PubMedCrossRef
136.
Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, et al. Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy. PLoS One. 2016;11:e0147145.PubMedPubMedCentralCrossRef
137.
Jacob L, Kostev K, Rathmann W, Kalder M. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. J Diabetes Complicat. 2016;30:1056–9.PubMedCrossRef
138.
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist. 2015;20:1236–44.PubMedPubMedCentralCrossRef
139.
Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014;9:e91818.PubMedPubMedCentralCrossRef
140.
Ki YJ, Kim HJ, Kim MS, Park CM, Ko MJ, Seo YS, et al. Association between metformin use and survival in non-metastatic rectal cancer treated with a curative resection: a nationwide population study. Cancer Res Treat. (Epub 2016 Jul 4).
141.
142.
Chong RW, Vasudevan V, Zuber J, Solomon SS. Metformin has a positive therapeutic effect on prostate cancer in patients with type 2 diabetes mellitus. Am J Med Sci. 2016;351:416–9.PubMedCrossRef
143.
Rêgo DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol. 2015;51:416–22.PubMedCrossRef
144.
Sayed R, Saad AS, El Wakeel L, Elkholy E, Badary O. Metformin addition to chemotherapy in stage IV non-small cell lung cancer: an open label randomized controlled study. Asian Pac J Cancer Prev. 2015;16:6621–6.PubMedCrossRef
145.
Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Metformin use and survival from lung cancer: a population-based cohort study. Lung Cancer. 2016;94:35–9.PubMedCrossRef
146.
Menamin ÚC, Murray LJ, Hughes CM, Cardwell CR. Metformin use and survival after colorectal cancer: a population-based cohort study. Int J Cancer. 2016;138:369–79.CrossRef
147.
Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:839–47.PubMedCrossRef
148.
Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. 2016;22:1076–85.PubMedCrossRef
149.
Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. The impact of metformin use on survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. (Epub 2016 Jun 29).
150.
Nayan M, Finelli A, Jewett MAS, Juurlink DN, Austin PC, Kulkarni GS, et al. Metformin use and kidney cancer outcomes in patients with diabetes: a propensity score analysis. Clin Genitourin Cancer. (Epub 2016 Jun 23).
151.
Shah RR. Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: combined subgroup analyses of the RECORD-1 and REACT trials. Clin Genitourin Cancer. (Epub 2016 Jul 21).
152.
Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015;107(3):djv006.PubMedPubMedCentralCrossRef
153.
Hanprasertpong J, Jiamset I, Geater A, Peerawong T, Hemman W, Kornsilp S. The effect of metformin on oncological outcomes in patients with cervical cancer with type 2 diabetes mellitus. Int J Gynecol Cancer. (Epub 2016 Nov 17).
154.
Jayalath VH, Ireland C, Fleshner NE, Hamilton RJ, Jenkins DJ. The relationship between metformin and serum prostate-specific antigen levels. Prostate. 2016;76:1445–53.PubMedPubMedCentralCrossRef
155.
Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372:1700–9.PubMedCrossRef
156.
Sequist LV, Soria JC, Camidge DR. Update to rociletinib data with the RECIST confirmed response rate. N Engl J Med. 2016;374:2296–7.PubMedCrossRef
157.
Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, et al. Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: combined subgroup analyses of the RECORD-1 and REACT trials. Clin Genitourin Cancer. 2016;14:406–14.PubMedPubMedCentralCrossRef
158.
Sequist LV, Rolfe L, Allen AR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;373:578–9.PubMedCrossRef
159.
Gong Z, Aragaki AK, Chlebowski RT, Manson JE, Rohan TE, Chen C, et al. Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women’s health initiative. Int J Cancer. 2016;138:1915–27.PubMedCrossRef
160.
Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, et al. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014;9:195–204.PubMedCrossRef
161.
Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer. 2016;138:2312–21.PubMedCrossRef
162.
Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22:2874–84.PubMedPubMedCentralCrossRef
163.
164.
Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–45.PubMedPubMedCentralCrossRef
165.
Li L, Huang W, Li K, Zhang K, Lin C, Han R, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget. 2015;6:43605–19.PubMedPubMedCentral
166.
Fasano M, Della Corte CM, Capuano A, Sasso FC, Papaccio F, Berrino L, et al. A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial. Clin Lung Cancer. 2015;16:57–9.PubMedCrossRef
Metadata
Title
Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
Author
Rashmi R. Shah
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2017
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-016-0485-y

Other articles of this Issue 3/2017

Drug Safety 3/2017 Go to the issue

Current Opinion

Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Original Research Article

The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis

Original Research Article

Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case–Control Study in Men of Subfertile Couples from the Netherlands

Original Research Article

Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study

Special Article

Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery

Systematic Review

Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis